β-Agonists and Death from Asthma

A. J. Woolcock, M. R. Sears, P. J. Barnes, H. W. Staudinger, J. F. Haas, Daniel J. Gottlieb, Bartolome R. Celli, Neil Pearce, Julian Crane, Carl Burgess, Richard Beasley, Rodney Jackson, Pierre Ernst, Samy Suissa, Jean François Boivin, Walter Spitzer, Ralph Horwitz, Brian Habbick, Donald Cockcroft, Mary McnuttSonia Buist, Benjamin Burrows, Michael D. Lebowitz

Research output: Contribution to journalLetterpeer-review

5 Scopus citations

Abstract

To the Editor: We write as concerned respiratory physicians to offer our views of the ways in which inhaled β2-adrenergic agonists should be used in the care of patients with asthma in the light of recent reports about their effects on the severity of asthma and the risk of death from asthma (Feb. 20 issue).1 2 3 4 5 There is little evidence that inhaled β-agonists have life-threatening side effects when used to reverse acute attacks of asthma, even when they are used in high doses. There are, however, reports that the regular use of high doses of isoproterenol6 , 7 and fenoterol5 causes…

Original languageEnglish (US)
Pages (from-to)354-357
Number of pages4
JournalNew England Journal of Medicine
Volume327
Issue number5
DOIs
StatePublished - Jul 30 1992

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'β-Agonists and Death from Asthma'. Together they form a unique fingerprint.

Cite this